The PE Ratio as of September 2024 (TTM) for Candel Therapeutics, Inc. (CADL) is -3.61

According to Candel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.61. This represents a change of 166.49% compared to the average of -1.35 of the last 4 quarters.

Candel Therapeutics, Inc. (CADL) Historical PE Ratio (quarterly & annually)

How has CADL PE Ratio performed in the past?

The mean historical PE Ratio of Candel Therapeutics, Inc. over the last ten years is -12.00. The current -3.61 PE Ratio has changed 2.91% with respect to the historical average. Over the past ten years (40 quarters), CADL's PE Ratio was at its highest in in the June 2022 quarter at 51.29. The PE Ratio was at its lowest in in the March 2020 quarter at -18.48.

Candel Therapeutics, Inc. (CADL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Candel Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Candel Therapeutics, Inc. (CADL) Average PE Ratio

How has CADL PE Ratio performed in the past?

The current PE Ratio of Candel Therapeutics, Inc. (CADL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Candel Therapeutics, Inc. (CADL) PE Ratio vs. Peers

How is CADL’s PE Ratio compared to its peers?

Candel Therapeutics, Inc.’s PE Ratio is less than Aerovate Therapeutics, Inc. (-0.62), less than Adagene Inc. (-2.86), greater than Acrivon Therapeutics, Inc. Common Stock (-4.23), greater than Rezolute, Inc. (-3.80), less than AN2 Therapeutics, Inc. (-0.47), less than Molecular Partners AG (-2.67), greater than Mineralys Therapeutics, Inc. (-4.63), greater than Pharvaris N.V. (-8.20), less than PepGen Inc. (-3.22), less than PMV Pharmaceuticals, Inc. (-1.58), less than Acurx Pharmaceuticals, Inc. (-1.87), less than Monopar Therapeutics Inc. (-1.18), less than Enochian Biosciences, Inc. (-1.24), less than Indaptus Therapeutics, Inc. (-0.78), less than Tempest Therapeutics, Inc. (-0.88), less than Comera Life Sciences Holdings, Inc. (-0.01), less than Forte Biosciences, Inc. (-0.39), less than Bionomics Limited (-0.18), greater than OKYO Pharma Limited (-6.11), greater than Anebulo Pharmaceuticals, Inc. (-4.99), less than Cingulate Inc. (-1.82),

Build a custom stock screener for Candel Therapeutics, Inc. (CADL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Candel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Candel Therapeutics, Inc. (CADL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Candel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.